毕得医药
(688073)
| 流通市值：20.00亿 | | | 总市值：42.03亿 |
| 流通股本：4323.42万 | | | 总股本：9088.29万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 811,377,889.62 | 532,207,309.99 | 262,669,977.5 | 1,091,858,561.97 |
| 营业收入 | 811,377,889.62 | 532,207,309.99 | 262,669,977.5 | 1,091,858,561.97 |
| 二、营业总成本 | 696,947,815.87 | 456,333,477.22 | 225,411,993.32 | 940,546,450.07 |
| 营业成本 | 477,309,328.92 | 321,954,244.55 | 160,517,623.25 | 655,120,131.68 |
| 税金及附加 | 4,100,758.52 | 2,441,504.24 | 1,025,276.59 | 5,137,913.72 |
| 销售费用 | 94,315,547.68 | 60,635,280.19 | 31,440,807.65 | 127,062,863.22 |
| 管理费用 | 81,024,454.72 | 53,230,049.84 | 24,653,471.92 | 119,550,943.45 |
| 研发费用 | 45,523,716.19 | 30,050,598.68 | 15,420,297.35 | 63,227,409.3 |
| 财务费用 | -5,325,990.16 | -11,978,200.28 | -7,645,483.44 | -29,552,811.3 |
| 其中:利息费用 | 4,231,686.97 | 3,404,174.98 | 856,539.19 | 2,530,435.16 |
| 其中:利息收入 | 18,154,660.61 | 13,385,141.73 | 7,322,689.04 | 27,983,759.54 |
| 加:公允价值变动收益 | 1,269,450.8 | -323,502.63 | -1,221,398.52 | -12,632,140.39 |
| 加:投资收益 | 1,509,336.6 | 967,790.34 | 435,243.4 | 3,759,981.22 |
| 资产处置收益 | 833,396.64 | 610,649.76 | 432,182.38 | 438,709.58 |
| 资产减值损失(新) | -21,223,248.36 | -12,421,528.51 | -6,931,767.23 | -18,263,044.45 |
| 信用减值损失(新) | -3,619,264.95 | -2,616,286.74 | -330,959.49 | -4,994,469.72 |
| 其他收益 | 9,087,820.69 | 1,983,839.66 | 1,546,551.46 | 7,008,019.03 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 102,287,565.17 | 64,074,794.65 | 31,187,836.18 | 126,629,167.17 |
| 加:营业外收入 | 334,774.76 | 197,043.79 | 136,932.44 | 59,847.02 |
| 减:营业外支出 | 230,780.14 | 17,670.88 | 14,538.18 | 692,242.81 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 102,391,559.79 | 64,254,167.56 | 31,310,230.44 | 125,996,771.38 |
| 减:所得税费用 | 18,537,666.99 | 12,415,103.01 | 5,235,287.44 | 17,550,472.6 |
| 六、净利润 | 83,853,892.8 | 51,839,064.55 | 26,074,943 | 108,446,298.78 |
| 持续经营净利润 | 83,853,892.8 | 51,839,064.55 | 26,074,943 | 108,446,298.78 |
| 归属于母公司股东的净利润 | 83,853,892.8 | 51,839,064.55 | 26,074,943 | 109,571,788.68 |
| 少数股东损益 | - | - | - | -1,125,489.9 |
| (一)基本每股收益 | 0.94 | 0.58 | 0.29 | 1.21 |
| (二)稀释每股收益 | 0.94 | 0.58 | 0.29 | 1.21 |
| 八、其他综合收益 | 3,372,706.74 | 376,362.85 | -339,064.78 | 282,987.35 |
| 归属于母公司股东的其他综合收益 | 3,372,706.74 | 376,362.85 | -339,064.78 | 282,987.35 |
| 九、综合收益总额 | 87,226,599.54 | 52,215,427.4 | 25,735,878.22 | 108,729,286.13 |
| 归属于母公司股东的综合收益总额 | 87,226,599.54 | 52,215,427.4 | 25,735,878.22 | 109,854,776.03 |
| 归属于少数股东的综合收益总额 | - | - | - | -1,125,489.9 |
| 公告日期 | 2024-10-24 | 2024-08-29 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |